title: Abiraterone acetate.
abstract: Abiraterone acetate (CB 7630; CB7630; JNJ-212082), the 3β-acetate prodrug of abiraterone, is structurally related to ketoconazole and is being developed by Cougar Biotechnology as a hormonal therapy for advanced prostate and breast cancers. As a selective inhibitor of adrenal androgens, it is thought to be a safer product than existing second-line hormonal therapies. This review discusses the key development milestones and therapeutic trials of this drug.
mesh_terms: D000069501:Abiraterone Acetate; D000726:Androgen Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000730:Androstadienes / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D011355:Prodrugs / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000726:Androgen Antagonists; D000730:Androstadienes; D018931:Antineoplastic Agents, Hormonal; D015507:Drugs, Investigational; D011355:Prodrugs; D000069501:Abiraterone Acetate